Evaluation of an immunoseparation method for quantitative measurement of remnant-like particle-cholesterol in serum and plasma

• Published in: Clinical chemistry (Baltimore, Md.) Vol. 44; no. 12; pp. 2490 - 2498
• Main Authors: Leary, Elizabeth Teng, Wang, Tao, Baker, Daniel J, Cilla, Donald D, Zhong, Jianhua, Warnick, G. Russell, Nakajima, Katsuyuki, Havel, Richard J
• Format: Journal Article
• Language: English
• Published: Washington, DC Am Assoc Clin Chem 01-12-1998; American Association for Clinical Chemistry
• Subjects: Adolescent; Adult; Aged; Apolipoproteins - blood; Biological and medical sciences; Blood Specimen Collection; Cardiac dysrhythmias; Cardiology. Vascular system; Cholesterol; Coronary Angiography; Coronary Disease - blood; Coronary Disease - diagnostic imaging; Female; Heart; Humans; Lipoproteins - blood; Male; Medical sciences; Middle Aged; Reagent Kits, Diagnostic; Reference Values; Triglycerides - blood; United States; Performance evaluation; Human; Biological fluid; Biological marker; Cardiovascular disease; Boundary value; Lipoprotein; Coronary heart disease; Cholesterol; Immunological method; Blood plasma; Clinical biology; Serum; Quantitative analysis
• ISSN: 0009-9147; 1530-8561
• DOI: 10.1093/clinchem/44.12.2490

Substantial evidence indicates that triglyceride-rich lipoprotein remnants are atherogenic. Additional research has, however, been limited by available methods for separation and quantification of remnants. We have evaluated an immunoseparation assay developed to measure cholesterol in remnant-like particles (RLP-C). This method uses monoclonal antibodies to human apolipoproteins B-100 and A-I to remove most of the apolipoprotein B-100-containing lipoproteins (namely LDL and nascent VLDL) and apolipoprotein A-I-containing lipoproteins (namely chylomicrons and HDL), leaving behind a fraction of triglyceride-rich lipoproteins, including chylomicron and VLDL remnants, both of which are enriched in apolipoprotein E. Cholesterol in the unbound fraction is measured with a sensitive enzymatic assay. The RLP-C concentration was highly correlated with total triglyceride-rich lipoproteins (sum of VLDL-cholesterol and IDL-cholesterol) separated by ultracentrifugation and by polyacrylamide gel electrophoresis (r = 0.86 and 0.76, respectively). The within-run and run-to-run imprecision (CV) of the assay was approximately 6% and 10%, respectively. The assay was not affected by hemoglobin up to 5000 mg/L (500 mg/dL), bilirubin up to 342 mmol/L (20 mg/dL), glucose up to 67 mmol/L (1200 mg/dL), or ascorbic acid up to 170 mmol/L (3.0 mg/dL). In 726 subjects (men, n = 364; women, n = 362) in the US, the 75th percentiles of RLP-C concentration were 0.17 mmol/L (6.6 mg/dL) and 0.23 mmol/L (8.8 mg/dL) in sera obtained after overnight fasting or randomly, respectively. A group of 151 patients from nine US centers and one Canadian center with coronary artery atherosclerosis established by angiography had higher median RLP-C concentrations than 302 gender- and age-matched controls (P <0.05). We conclude that the RLP-C assay compares favorably to ultracentrifugation and electrophoresis and provides a convenient and economical approach to measure triglyceride-rich lipoprotein remnants in routine clinical laboratories.